Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source

Allogeneic hematopoietic stem cell transplantation (HSCT) is the best curative option for children with high-risk acute leukemia. However, only 30% of patients have a compatible familial donor, and for minorities, only one in three have an unrelated matched donor1. This limits the possibility of transplant for these patients, especially in countries with limited resources and access difficulties to unrelated cord blood units or bone marrow donors. Fortunately, a partially compatible (haploidentical) related donor is available in at least 95% of cases2, and the use of cyclophosphamide post-transplantation has allowed the use of haploidentical hematopoietic progenitor cells without the necessity of ex vivo T-cell depletion3,4.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research